Baylor receives patent for islet cell transplantation in patients with type1 diabetes, chronic pancreatitis

Baylor Research Institute has been awarded a patent from the U.S. Patent Office for a potential strategy to improve the outcomes of islet cell transplantation for patients with type 1 diabetes and chronic pancreatitis.

The Baylor research team determined that withaferin A (WA), a plant-derived compound with strong anti-inflammatory and anti-oxidant properties, is a strong inhibitor of the inflammatory response in islets, protecting them against cytokine-induced cell damage while improving the survival of transplanted islets. The results suggest that WA could be incorporated as an adjunctive treatment to current immunosuppressive therapies to improve islet transplant outcome.

"Currently, no anti-inflammatory compound with broad benefits such as withaferin A is used in the islet transplant field. The experimental research performed at Baylor on this compound has improved the basic understanding of the molecular mechanism involved in islet damage during the peritransplant period," said Bashoo Naziruddin, PhD, director of the Islet Cell Laboratory at Baylor University Medical Center at Dallas.

The Baylor research team was the first to report that when islet cells are injected back into the patient they are subject to a severe inflammatory reaction, which can damage the islet cells. Using molecular analysis, they obtained evidence that the inflammatory reaction occurs within hours of the transplant.

"Islet cell transplant continues to show promise for treating patients with type 1 diabetes. Auto islet cell transplant already is used successfully to treat patients with chronic pancreatitis," Dr. Naziruddin said. "We hope the use of WA will strengthen existing immunosuppressive strategies to improve current islet transplant outcomes by preserving the mass and function of engrafted islets."

In addition to Dr. Naziruddin, inventors of the patented procedure include Marlon Levy, MD, FACS, medical director, Islet Cell Transplant Program, Baylor Health Care System, Shinichi Matsumoto, MD, PhD, former director of the Islet Cell Laboratory at Baylor All Saints Medical Center at Fort Worth, and Han Peng, graduate student.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Studies reveal the promise of newly engineered bispecific antibodies against tumor cells